Target Price | $17.75 |
Price | $9.72 |
Potential |
82.61%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Amicus Therapeutics, Inc. 2025 .
The average Amicus Therapeutics, Inc. target price is $17.75.
This is
82.61%
register free of charge
$21.00
116.05%
register free of charge
$14.00
44.03%
register free of charge
|
|
A rating was issued by 13 analysts: 11 Analysts recommend Amicus Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amicus Therapeutics, Inc. stock has an average upside potential 2025 of
82.61%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 399.36 | 525.82 |
21.30% | 31.67% | |
EBITDA Margin | -16.43% | 11.76% |
72.83% | 171.57% | |
Net Margin | -38.14% | -11.32% |
48.73% | 70.32% |
13 Analysts have issued a sales forecast Amicus Therapeutics, Inc. 2024 . The average Amicus Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Amicus Therapeutics, Inc. EBITDA forecast 2024. The average Amicus Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Amicus Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Amicus Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.51 | -0.20 |
37.80% | 60.78% | |
P/E | negative | |
EV/Sales | 5.89 |
10 Analysts have issued a Amicus Therapeutics, Inc. forecast for earnings per share. The average Amicus Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Amicus Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Amicus Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.